Nipro Corp
Company Profile
Business description
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
Contact
3-9-3 Honjo-Nishi Kita-ku
Osaka531-8510
JPNT: +81 663722331
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 March 2025
Employees
39,233
Stocks News & Analysis
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
stocks
These 2 ASX stocks look materially overvalued after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,811.50 | 11.90 | 0.14% |
CAC 40 | 8,042.19 | 13.29 | 0.17% |
DAX 40 | 22,148.03 | 110.20 | 0.50% |
Dow JONES (US) | 44,368.56 | 225.09 | -0.50% |
FTSE 100 | 8,807.44 | 30.05 | 0.34% |
HKSE | 22,187.17 | 329.25 | 1.51% |
NASDAQ | 19,649.95 | 6.10 | 0.03% |
Nikkei 225 | 39,484.35 | 520.65 | 1.34% |
NZX 50 Index | 12,889.17 | 24.78 | -0.19% |
S&P 500 | 6,051.97 | 16.53 | -0.27% |
S&P/ASX 200 | 8,548.50 | 13.20 | 0.15% |
SSE Composite Index | 3,342.22 | 4.17 | -0.12% |